Asian study of clopidogrel (ASCLOP) responsiveness: The contributions of genetic and non-genetic factors

International Journal of Cardiology

Volumn 171, Issue 2, 2014, Pages

  Tan, Doreen S Y ^a   Yeo, Angie H L ^b   Ho, Han Kiat ^b   Wee, Hwee Lin ^b   Ong, Hean Yee ^a  

^a KHOO TECK PUAT HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Asian; Clopidogrel; CYP2C19; CYP3A; Dihydropyridine; PON1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CLOPIDOGREL; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; DIHYDROPYRIDINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; PROTON PUMP INHIBITOR;

ABCB1 GENE; ADULT; CHINESE; CONTROLLED STUDY; CORONARY STENT; CYP2B6 GENE; CYP2C19 GENE; CYP3A5 GENE; DRUG RESPONSE; FEMALE; GENETIC VARIABILITY; HEREDITY; HUMAN; IN-STENT RESTENOSIS; INDIAN; ISCHEMIC HEART DISEASE; LETTER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLATELET REACTIVITY; PON1 GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ASIAN; CLOPIDOGREL; CYP2C19; CYP3A; DIHYDROPYRIDINE; PON1;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84892866910     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.11.126     Document Type: Article

References (10)

1. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 23 2003 2908 2913
2. S. Matetzky, B. Shenkman, and V. Guetta et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 25 2004 3171 3175
3. F. Sofi, R. Marcucci, A.M. Gori, B. Giusti, R. Abbate, and G.F. Gensini Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis Thromb Haemost 103 4 2010 841 848
4. B. Chandrasekar, and J.-F. Tanguay Platelets and restenosis J Am Coll Cardiol 35 3 2000 555 562
5. J.A. Talameh, and H.L. McLeod PON1 Q192R and clopidogrel: a case of the winner's curse or inadequate replication? Clin Pharmacol Ther 90 6 2011 771 774
6. S.-C. Lee, S.-S. Ng, and J. Oldenburg et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population Clin Pharmacol Ther 79 3 2006 197 205
7. A.M. Harmsze, K. Robijns, and J.W. van Werkum et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response Thromb Haemost 103 5 2010 920 925
8. D.J. Quinlan, J.W. Eikelboom, and S.G. Goodman et al. Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes Eur Heart J 32 18 2011 2256 2265
9. J.J. DiNicolantonio, and V.L. Serebruany Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports Ther Adv Cardiovasc Dis 7 1 2013 5 9
10. V.L. Serebruany, J.J. Dinicolantonio, M.M. Can, I.V. Pershukov, and W. Kuliczkowski Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive Cardiology 126 1 2013 35 40